Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme, BD Technologies Expand HT Assay Development Partnership

NEW YORK, March 2 (GenomeWeb News) - Tranzyme Pharma today said that it has expanded a strategic alliance it began in 2002 with BD Technologies, a unit of Becton, Dickinson and Company.

The collaboration is focused on the development and commercialization of high-throughput assays for drug discovery.

Under the expanded alliance, BD will continue to receive access to Tranzyme's TranzVector and TExT proprietary gene delivery and expression technologies, and the two companies will also jointly explore the use of Tranzyme's technologies in specific cell types of interest to BD.

BD will provide R&D funding to Tranzyme and will have rights to market any commercial products that result from the use of Tranzyme's technology. BD said it would pay Tranzyme royalties on the sale of these products.

Other financial details of the agreement were not disclosed.

Tranzyme is a member of the BD Technologies BioVenture Center Incubator in Research Triangle Park, NC.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.